Privia Health Files Proxy Materials

TL;DR

PRVA proxy update filed, no fee. Standard procedure.

AI Summary

Privia Health Group, Inc. filed a Definitive Additional Materials (DEFA14A) on May 12, 2025. This filing relates to the company's proxy statement and indicates no fee was required for this filing. The company's principal executive offices are located at 950 N. Glebe Rd., Suite 700, Arlington, VA 22203.

Why It Matters

This filing is a routine regulatory submission for Privia Health Group, Inc., providing updated proxy information to shareholders and the SEC.

Risk Assessment

Risk Level: low — This filing is a standard DEFA14A, indicating routine corporate communications rather than significant new events or risks.

Key Players & Entities

• Privia Health Group, Inc. (company) — Registrant
• 950 N. Glebe Rd., Suite 700, Arlington, VA 22203 (location) — Business Address
• PH Group Parent Corp. (company) — Former Company Name

FAQ

From the Filing

0001193125-25-117273.txt : 20250512 0001193125-25-117273.hdr.sgml : 20250512 20250512070601 ACCESSION NUMBER: 0001193125-25-117273 CONFORMED SUBMISSION TYPE: DEFA14A PUBLIC DOCUMENT COUNT: 3 FILED AS OF DATE: 20250512 DATE AS OF CHANGE: 20250512 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Privia Health Group, Inc. CENTRAL INDEX KEY: 0001759655 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HEALTH SERVICES [8000] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEFA14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-40365 FILM NUMBER: 25932555 BUSINESS ADDRESS: STREET 1: 950 N. GLEBE RD., SUITE 700 CITY: ARLINGTON STATE: VA ZIP: 22203 BUSINESS PHONE: 571-366-8850 MAIL ADDRESS: STREET 1: 950 N. GLEBE RD., SUITE 700 CITY: ARLINGTON STATE: VA ZIP: 22203 FORMER COMPANY: FORMER CONFORMED NAME: PH Group Parent Corp. DATE OF NAME CHANGE: 20181120 DEFA14A 1 d833624ddefa14a.htm DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant  ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240.14a-12 Privia Health Group, Inc. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check all boxes that apply): ☒ No fee required ☐ Fee paid previously with preliminary material ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 Privia Health Group, Inc. 950 N. Glebe Rd., Suite 700 Arlington, VA 22203 Telephone: (571) 366-8850 SUPPLEMENT TO THE PROXY STATEMENT FOR THE 2025 ANNUAL MEETING OF STOCKHOLDERS Dear Stockholders: We are writing to provide certain clarifications in connection with the 2025 Annual Meeting of Stockholders (the “ 2025 Annual Meeting ”) of Privia Health Group, Inc. (the “ Company ”) on Wednesday, May 21, 2025 at 11:00 a.m. Eastern Time. This communication supplements the definitive proxy statement in connection with the 2025 Annual Meeting, filed with the Securities and Exchange Commission on April 5, 2025 (the “ 2025 Proxy Statement ”). The Company is providing the following clarifications in light of feedback from Institutional Shareholder Services (“ ISS ”) in its report dated May 2, 2025 (the “ ISS Report ”). Executive Summary The Company’s position with respect to its classified board structure has not changed and it does not intend to maintain a classified board structure in perpetuity. As disclosed in the 2025 Proxy Statement, the board intends to continue to evaluate the feasibility of the classified board on an ongoing basis with input from stockholders and expects that its governance structure, including its classified board, will evolve as the Company grows, the market matures, and the Company responds to feedback from its stockholders. The board and the Company’s position is consistent with its approach in its proxy statement for the 2024 annual meeting of stockholders (the “ 2024 Proxy Statement ”), and to which ISS did not object in its 2024 report. ISS Report With respect to Proposal 1 regarding the election of directors, the ISS Report recommends a WITHHOLD vote for governance committee member Pamela Kimmet “given the board’s failure to remove, or subject to a sunset requirement, the classified board.” Specifically, the ISS Report notes the Company “did not provide a commitment that it does not inten